Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Net Margin (2016 - 2025)

Historic Net Margin for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to 40.15%.

  • Vanda Pharmaceuticals' Net Margin fell 289700.0% to 40.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 39.68%, marking a year-over-year decrease of 311000.0%. This contributed to the annual value of 9.51% for FY2024, which is 108100.0% down from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Net Margin is 40.15%, which was down 289700.0% from 51.7% recorded in Q2 2025.
  • Vanda Pharmaceuticals' 5-year Net Margin high stood at 14.14% for Q2 2021, and its period low was 58.89% during Q1 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' median Net Margin value was 0.46% (recorded in 2023), while the average stood at 6.68%.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Net Margin skyrocketed by 158500bps in 2023 and then plummeted by -501500bps in 2025.
  • Vanda Pharmaceuticals' Net Margin (Quarter) stood at 10.44% in 2021, then grew by 2bps to 10.68% in 2022, then crashed by -149bps to 5.28% in 2023, then plummeted by -75bps to 9.24% in 2024, then plummeted by -335bps to 40.15% in 2025.
  • Its last three reported values are 40.15% in Q3 2025, 51.7% for Q2 2025, and 58.89% during Q1 2025.